<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018730</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F30</org_study_id>
    <nct_id>NCT03018730</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)</brief_title>
  <official_title>An Open Label Study of the Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label switch over study to assess the safety and efficacy of PRX-102
      (pegunigalsidase alfa). Patients treated with agalsidase alfa for at least 2 years and on a
      stable dose (&gt;80% labelled dose/kg) for at least 6 months. Patients will be screened and
      evaluated over 3 months while continuing on agalsidase alfa. Following the screening period,
      the patient will be enrolled and switched from their agalsidase alfa treatment to receive
      intravenous (IV) infusions of PRX-102 1 mg/kg every two weeks for 12 months. No more than 25%
      of treated patients will be female.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Throughout the 12 months study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean annualised change in eGFR</measure>
    <time_frame>Every 4 weeks for 12 months</time_frame>
    <description>Mean annualised change in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass Index (g/m2) preferably by MRI</measure>
    <time_frame>Every 6 months for 12 months</time_frame>
    <description>Left Ventricular Mass Index (g/m2) preferably by MRI (ECG can be used as an alternative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lyso-Gb3</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Gb3</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Lyso-Gb3</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein/Creatinine ratio</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
    <description>Protein/Creatinine ratio spot urine test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of pain medication use</measure>
    <time_frame>Every 2 weeks for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance (Stress Test)</measure>
    <time_frame>Every 6 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Brief Pain Inventory (BPI)</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mainz Severity Score Index (MSSI)</measure>
    <time_frame>Every 6 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EQ-5D-5L</measure>
    <time_frame>Every 6 months for 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>PRX-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 infusion every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRX-102 (pegunigalsidase alfa)</intervention_name>
    <description>PRX-102 1 mg/kg every 2 weeks</description>
    <arm_group_label>PRX-102</arm_group_label>
    <other_name>pegunigalsidase alfa</other_name>
    <other_name>Recombinant human alpha galactosidase-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-60 years

          2. A documented diagnosis of Fabry disease

          3. Males: plasma and/or leucocyte alpha galactosidase activity (by activity assay) less
             than lower limit of normal according to laboratory range and one or more of the
             characteristic features of Fabry disease i. Neuropathic pain ii. Cornea verticillata
             iii. Clustered angiokeratoma

          4. Females: historical genetic test results consistent with Fabry mutations, or in the
             case of novel mutations a first degree male relative with Fabry disease, and one or
             more of the characteristic features of Fabry disease i. Neuropathic pain ii. Cornea
             verticillata iii. Clustered angiokeratoma

          5. Treatment with agalsidase alfa for at least 2 years and on a stable dose (&gt;80%
             labelled dose/kg) for at least 6 months

          6. eGFR ≥ 40 ml/min/1.73 m2 by CKD-EPI equation

          7. Availability of at least 2 historical serum creatinine evaluations since starting
             agalsidase alfa treatment and not more than 2 years

          8. Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically acceptable method of contraception, not including the rhythm
             method

        Exclusion Criteria:

          1. History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase alfa

          2. History of renal dialysis or transplantation

          3. History of acute kidney injury in the 12 months prior to screening, including specific
             kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic
             renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as well as
             extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive
             nephropathy)

          4. Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
             therapy initiated or dose changed in the 4 weeks prior to screening

          5. Urine protein to creatinine ratio (UPCR) &gt; 0.5 g/g and not treated with an ACE
             inhibitor or ARB

          6. Known history of hypersensitivity to Gadolinium contrast agent

          7. Females who are pregnant, planning to become pregnant during the study, or are breast
             feeding

          8. Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period
             before screening

          9. Congestive heart failure NYHA Class IV

         10. Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before
             screening

         11. Presence of any medical, emotional, behavioral or psychological condition that, in the
             judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul Chertkoff, MD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raul Chertkoff, MD</last_name>
    <phone>+972-54-2228472</phone>
    <email>raul@protalix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Nicholls, MD</last_name>
      <phone>61393427000</phone>
      <email>kathy.nicholls@mh.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Donna North</last_name>
      <phone>+61 393424219</phone>
      <email>donna.north@mh.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Nicholls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael West, MD</last_name>
      <phone>+1 902 473 4023</phone>
      <email>mlwest@dal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dawn Menon</last_name>
      <phone>+1 9024731156</phone>
      <email>Dawn.Menon@nshealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ales Linhart, MD</last_name>
      <phone>420224962605</phone>
      <email>alinh@lf1.cuni.cz</email>
    </contact>
    <contact_backup>
      <last_name>Zuzana Kristofova</last_name>
      <phone>420 224 962 605</phone>
      <email>zuzana.kristofova@vfn.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Ales Linhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Wanner, MD</last_name>
      <phone>49 931 20139030</phone>
      <email>wanner_c@klinik.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Wanner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjam Langeveld, MD</last_name>
      <phone>31205666071</phone>
      <email>m.langeveld@amc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Shirley Klein</last_name>
      <phone>31205665972</phone>
      <email>shirley.klein@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Mirjam Langeveld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Tøndel, MD</last_name>
      <phone>+47 55975962</phone>
      <email>camilla.tondel@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Jorunn Syltoy</last_name>
      <phone>+47 55971490</phone>
      <email>jorunn.johanne.jacobsen.syltoy@helse-bergen.no</email>
    </contact_backup>
    <investigator>
      <last_name>Camilla Tøndel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Slovenj Gradec</name>
      <address>
        <city>Slovenj Gradec</city>
        <zip>SI-2380</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan Vujkovac, MD</last_name>
      <phone>00386 2 8823 708</phone>
      <email>bojan.vujkovac@guest.arnes.si</email>
    </contact>
    <investigator>
      <last_name>Bojan Vujkovac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Quiron Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Giraldo, MD</last_name>
      <phone>34670285339</phone>
      <email>giraldocastellano@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Beatriz Escuder</last_name>
      <phone>34676605758</phone>
      <email>bea.escuderazuara@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pilar Giraldo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Metabolism and Systems Research</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2UR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarekegn G Hiwot, MD</last_name>
      <phone>+44 (0)121 371 6982</phone>
      <email>t.g.hiwot@bham.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Tarekegn G Hiwot, MD</last_name>
      <phone>+44 (0)121 371 6982</phone>
      <email>tarekegn.hiwot@uhb.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Tarekegn G Hiwot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Deegan, MD</last_name>
      <phone>441223245151</phone>
      <email>patrick.deegan@addenbrookes.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Morris-Bacon</last_name>
      <phone>441223 274634</phone>
      <phone_ext>4634</phone_ext>
      <email>lisa.morris-bacon@addenbrookes.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Deegan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derralynn Hughes, MD</last_name>
      <phone>4402077940500</phone>
      <phone_ext>22496</phone_ext>
      <email>rmgvdah@ucl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Allison Warwick</last_name>
      <phone>44 0207 7940500</phone>
      <phone_ext>22488</phone_ext>
      <email>allison.warwick@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Derralynn Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Jovanovic, MD</last_name>
      <phone>+441612064365</phone>
      <email>ana.jovanovic@srft.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Marie Meehan</last_name>
      <phone>+441612064192</phone>
      <email>Marie.Meehan@srft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ana Jovanovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>Enzyme-Replacement Therapy</keyword>
  <keyword>pegunigalsidase alfa</keyword>
  <keyword>PRX-102</keyword>
  <keyword>alpha galactosidase-A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

